MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study

AIM: To compare the efficacy, safety, and tolerability of abemaciclib plus endocrine therapy (ET) versus ET alone in postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) from China, Brazil, India, and South Af...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qing Yuan, Sun, Tao, Yin, Yong Mei, Li, Hui Ping, Yan, Min, Tong, Zhong Sheng, Oppermann, Christina P., Liu, Yun Peng, Costa, Romulo, Li, Man, Cheng, Ying, Ouyang, Qu Chang, Chen, Xi, Liao, Ning, Wu, Xin Hong, Wang, Xiao Jia, Feng, Ji Feng, Hegg, Roberto, Kanakasetty, G.B., Coccia-Portugal, Maria A., Han, Ru Bing, Lu, Yi, Chi, Hai Dong, Jiang, Ze Fei, Hu, Xi Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586037/
https://www.ncbi.nlm.nih.gov/pubmed/33149768
http://dx.doi.org/10.1177/1758835920963925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586037/
https://www.ncbi.nlm.nih.gov/pubmed/33149768
http://dx.doi.org/10.1177/1758835920963925

Ejemplares similares